



## ASX ANNOUNCEMENT – COMPLETION OF PRIVATE PLACEMENT

**Minnesota, United States and Melbourne, Australia – 9 September 2016.** Osprey Medical, Inc. (ASX:OSP) (**Osprey** or **Company**) is pleased to announce that 35,714,286 CHESS Depositary Interests (**CDIs**) (the equivalent of 17,857,143 shares of Common Stock) have today been allotted to complete the issue of Tranche 2 of the Placement announced on 4 August 2016.

The allocation today completes the 100 Million CDI allocation under the Placement.

### About Osprey

Osprey Medical is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker IDI Heart and Diabetes Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage. The Company's DyeVert™ System is a next-generation product that reduces contrast while maintaining image quality in a self-adjusting easy-to-use design. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Media	Investors	Company
Gavin Lower Buchan Consulting T: (613) 8866 1215 <a href="mailto:glower@buchanwe.com.au">glower@buchanwe.com.au</a>	Rebecca Wilson Buchan Consulting M: (61) 417 382 391 <a href="mailto:rwilson@buchanwe.com.au">rwilson@buchanwe.com.au</a>	Doug Schoenberg VP of Marketing T: (952) 955 8230 <a href="mailto:dschoenberg@ospreymed.com">dschoenberg@ospreymed.com</a>